ATE273962T1 - 5-phenyl-pyrimidine derivate - Google Patents

5-phenyl-pyrimidine derivate

Info

Publication number
ATE273962T1
ATE273962T1 AT00935104T AT00935104T ATE273962T1 AT E273962 T1 ATE273962 T1 AT E273962T1 AT 00935104 T AT00935104 T AT 00935104T AT 00935104 T AT00935104 T AT 00935104T AT E273962 T1 ATE273962 T1 AT E273962T1
Authority
AT
Austria
Prior art keywords
phenyl
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
AT00935104T
Other languages
English (en)
Inventor
Michael Boes
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE273962T1 publication Critical patent/ATE273962T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT00935104T 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivate ATE273962T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99110482 1999-05-31
PCT/EP2000/004702 WO2000073278A2 (en) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE273962T1 true ATE273962T1 (de) 2004-09-15

Family

ID=8238270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935104T ATE273962T1 (de) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivate

Country Status (36)

Country Link
US (1) US6756380B1 (de)
EP (1) EP1187814B1 (de)
JP (1) JP3590591B2 (de)
KR (1) KR100478369B1 (de)
CN (1) CN1187338C (de)
AR (1) AR024145A1 (de)
AT (1) ATE273962T1 (de)
AU (1) AU769265B2 (de)
BR (1) BR0011097A (de)
CA (1) CA2375670C (de)
CO (1) CO5170529A1 (de)
CZ (1) CZ20014273A3 (de)
DE (1) DE60013127T2 (de)
DK (1) DK1187814T3 (de)
ES (1) ES2225144T3 (de)
GC (1) GC0000338A (de)
HK (1) HK1046411B (de)
HR (1) HRP20010867A2 (de)
HU (1) HU225016B1 (de)
IL (2) IL146519A0 (de)
JO (1) JO2308B1 (de)
MA (1) MA26794A1 (de)
MX (1) MXPA01011704A (de)
MY (1) MY136258A (de)
NO (1) NO321334B1 (de)
NZ (1) NZ515408A (de)
PE (1) PE20010203A1 (de)
PL (1) PL353492A1 (de)
PT (1) PT1187814E (de)
RU (1) RU2244710C2 (de)
SI (1) SI1187814T1 (de)
TR (1) TR200103460T2 (de)
TW (1) TWI263638B (de)
WO (1) WO2000073278A2 (de)
YU (1) YU85001A (de)
ZA (1) ZA200109496B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP2004503542A (ja) 2000-06-13 2004-02-05 ビーエーエスエフ　アクチェンゲゼルシャフト 殺真菌性５−フェニル置換２−（シアノアミノ）ピリミジン誘導体
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
CN1665506A (zh) 2002-07-02 2005-09-07 霍夫曼-拉罗奇有限公司 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
EP1689403A4 (de) * 2003-11-10 2007-09-05 Synta Pharmaceuticals Corp Heteroaryl-hydrazon-verbindungen
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
SMAP200600037A (it) * 2004-04-22 2006-11-22 Procter & Gamble Uree trisostituite come inibitori di citochina
WO2006053227A2 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2014145873A2 (en) 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
WO2016021562A1 (ja) * 2014-08-06 2016-02-11 キッセイ薬品工業株式会社 シアノチオフェン誘導体
US10420341B2 (en) * 2015-01-30 2019-09-24 Basf Se Herbicidal phenylpyrimidines
BR112018076700A2 (pt) 2016-07-20 2019-04-02 Basf Se composições herbicida e seu uso e método de controle da vegetação indesejada
US11180470B2 (en) 2016-07-25 2021-11-23 Basf Se Herbicidal pyrimidine compounds
CN109561685A (zh) 2016-07-25 2019-04-02 巴斯夫欧洲公司 除草的嘧啶化合物
BR112018077111A2 (pt) 2016-07-26 2019-04-02 Basf Se uso de compostos de pirimidina, compostos de pirimidina, mistura herbicida, composições herbicidas, método para controlar vegetação indesejada e uso das composições
EP3490381A1 (de) 2016-07-27 2019-06-05 Basf Se Herbizide pyrimidinverbindungen
AU2017303138A1 (en) 2016-07-28 2019-01-03 Basf Se Herbicidal pyrimidine compounds
AU2018283422A1 (en) 2017-06-14 2019-12-19 Basf Se Herbicidal pyrimidine compounds
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121373A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
CN112955443A (zh) * 2018-09-19 2021-06-11 拜耳公司 具有除草活性的取代的苯基嘧啶酰肼

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
AR208171A1 (es) 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
AU726522B2 (en) 1995-09-01 2000-11-09 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions

Also Published As

Publication number Publication date
AR024145A1 (es) 2002-09-04
HK1046411A1 (en) 2003-01-10
CO5170529A1 (es) 2002-06-27
MY136258A (en) 2008-09-30
JP3590591B2 (ja) 2004-11-17
ES2225144T3 (es) 2005-03-16
DE60013127D1 (de) 2004-09-23
DK1187814T3 (da) 2004-12-20
US6756380B1 (en) 2004-06-29
HK1046411B (zh) 2005-05-27
CA2375670A1 (en) 2000-12-07
KR20020003399A (ko) 2002-01-12
NO321334B1 (no) 2006-04-24
YU85001A (sh) 2004-09-03
HRP20010867A2 (en) 2003-04-30
NO20015701L (no) 2001-11-22
JP2003500477A (ja) 2003-01-07
AU5070800A (en) 2000-12-18
TWI263638B (en) 2006-10-11
NZ515408A (en) 2004-02-27
JO2308B1 (en) 2005-09-12
EP1187814A2 (de) 2002-03-20
CZ20014273A3 (cs) 2002-05-15
NO20015701D0 (no) 2001-11-22
HUP0201527A2 (en) 2002-08-28
EP1187814B1 (de) 2004-08-18
RU2244710C2 (ru) 2005-01-20
MXPA01011704A (es) 2002-05-14
TR200103460T2 (tr) 2002-05-21
SI1187814T1 (en) 2004-12-31
HU225016B1 (en) 2006-05-29
ZA200109496B (en) 2003-02-17
MA26794A1 (fr) 2004-12-20
PE20010203A1 (es) 2001-02-15
AU769265B2 (en) 2004-01-22
CN1187338C (zh) 2005-02-02
IL146519A0 (en) 2002-07-25
WO2000073278A3 (en) 2001-07-05
PL353492A1 (en) 2003-11-17
HUP0201527A3 (en) 2005-01-28
GC0000338A (en) 2007-03-31
IL146519A (en) 2006-12-10
CN1353696A (zh) 2002-06-12
BR0011097A (pt) 2002-03-19
DE60013127T2 (de) 2005-09-08
CA2375670C (en) 2009-09-29
KR100478369B1 (ko) 2005-03-24
WO2000073278A2 (en) 2000-12-07
PT1187814E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DE60009147D1 (de) Admantan derivate
IS2116B (is) 4-fenyl-pyridin afleiður
NO20021077L (no) Amino-triazolopyridin-derivater
DE60009747D1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
ATE273980T1 (de) 6-phenylpyrrolopyrimidindion derivate
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
ATE317389T1 (de) 4-phenyl-pyrimidine derivate
ATE293592T1 (de) Resorcinderivate
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
DE69904738D1 (de) 2-phenylpyran-4-one derivate
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE60143905D1 (de) Phtalazinon derivate
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
ATE269316T1 (de) 2-phenylpyran-4-on derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187814

Country of ref document: EP

REN Ceased due to non-payment of the annual fee